The prevalence of businesses selling autologous stem cell-based interventions to patients in Australia has raised serious concerns about how weaknesses in regulation have enabled the emergence of an industry that engages in aggressive marketing of unproven treatments to patients. Little is known about how patients experience this marketing and their subsequent interactions with practitioners. This paper reports results from 15 semistructured interviews with patients and carers, and also draws upon discussion conducted with patients, carers and family members (22 participants) in a workshop setting. We explore how Australian patients and carers understand and experience these interventions, and how their presumptions about the ethics of medical practice, and the regulatory environment in Australia have conditioned their preparedness to undergo unproven treatments.
CITATION STYLE
Waldby, C., Hendl, T., Kerridge, I., Lipworth, W., Lysaght, T., Munsie, M., & Stewart, C. (2020, January 1). The direct-to-consumer market for stem cell-based interventions in Australia: Exploring the experiences of patients. Regenerative Medicine. Future Medicine Ltd. https://doi.org/10.2217/rme-2019-0089
Mendeley helps you to discover research relevant for your work.